drugset / Trial / NCT03585530

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

NCT03585530

Phase 2 Unknown 32 enrolled Huai'an First People's Hospital
NaSingle-groupOpen-labelTreatment

Summary

Concurrent chemoradiotherapy is one of the curative options for esophageal squamous cell carcinoma. We evaluated the efficacy and toxicity of raltitrexed with concurrent radiotherapy in elderly patients with esophageal cancer.

Timeline

Start
2018-09-05
Primary completion
2022-01-30
Completion
2022-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltitrexed Small molecule 2.6 mg/m2